ContraFect - CFRX Stock Forecast, Price & News

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. WBB Securities upgraded ContraFect to a "strong-buy" rating and set a $7.00 target price for the company in a report on Wednesday, June 8th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $1.00 target price (down from $15.00) on shares of ContraFect in a report on Thursday, July 14th. SVB Leerink lowered ContraFect from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $9.00 to $1.00 in a report on Thursday, July 14th. Maxim Group lowered ContraFect from a "buy" rating to a "hold" rating in a report on Thursday, July 14th. Finally, StockNews.com began coverage on ContraFect in a report on Tuesday. They issued a "sell" rating for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $4.50.

ContraFect Price Performance

ContraFect stock opened at $0.32 on Thursday. ContraFect has a 1-year low of $0.28 and a 1-year high of $4.54. The stock has a market cap of $12.42 million, a PE ratio of -0.26 and a beta of 0.05. The stock's fifty day moving average is $1.76 and its two-hundred day moving average is $2.87.

ContraFect (NASDAQ:CFRX - Get Rating) last posted its earnings results on Monday, May 16th. The biotechnology company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). On average, research analysts expect that ContraFect will post -1.29 earnings per share for the current fiscal year.